from the Sugen thread, Miljenko said...
One example is CNSI or IPIC and their
stroke candidates. One tricky pony. Failed
and company is going down, down.
Miljenko, your posts are usually terrific
and I very much respect what you have to
say on these biotechs. However, I think that
calling Cambridge NeuroScience a "one trick
pony" is not at all a fair assesment, at least
now now after a couple of growth factor deals
have happened.
Begin reading here...This fellow has done
a pretty good job of putting down all that
is known and unknown regarding cnsi. You
cannot get to the thread very easily because
of the move to otc:bb right now, but the
thread is still active. Posts 1300-4 should
be read. A few words are not spelled correctly,
but otherwise I think the remarkable access
that this fella has to the CEO gives us a
genuine look at the prospects for this company.
I do not think any of what has been posted is
made up...do you?
The bottom line for me is Bayer deal is terrific
and cnsi is a $4 stock in the next year as their
CNS lead rhGGF2 goes to several IND filings.
messages.yahoo.com
"YukonHusky" wrote this in Yahoo post 1301
e.) Bayer: Wilcox said that he was "greatly upset"
with the market's reaction to the Bayer announcement.
Wilcox indicated that the Bayer deal was "a huge afformation
of a CNSI program/drug" and that IF Bayer took the MS drug
to Phase III clinical trials, Bayer "would have to spend
somewhere in the neighborhood of $200 to $300 million dollars
in developmental costs which, in turn, would produce a **tremendous
amount of royalty payments to CNSI."** Because of the market's
"disappointing" reaction, Wilcox told me that he has "given up
trying to predict how the market is going to react to corporate development announcements from the company." As far as the
agreement is concerned, like the Creative deal, CNSI and Bayer
have decided NOT to divulge how the cash payments will be paid,
but, Wilcox did tell me that the payments will be backend-loaded
and that "the bulk of the cash will be paid out by fourth year of
the agreement." Wilcox did say that the MS drug is further along in
its development than the Creative drug is - BUT BOTH drugs are years
away and alot of necessary developmental successess BEFORE either
or both of them will be brought to market;
also in post 1302
(j.) Merger/Acquisition?: Wilcox hinted to me that the board
has authorized him (and Wilcox admitted that it is in his best
interest as well) to explore all discussions to maximize shareholder
value "IN THE SHORT TERM." For obvious reasons, Wilcox would NOT tell
me whether he has had or is currently involved in merger discussions.
However, Wilcox said that any sale of the company would allow CNSI
shareholders (as well as CNSI option-holding "insiders") to benefit
from the development of the company's drugs .
When I pressed him as to what an acquiring company would get from
CNSI with some of its important drugs already in developmental
partnerships, Wilcox told me** cash, other promising drugs currently
NOT involved in corporate partnerships** and POSSIBLE lucrative future
royalty streams from Bayer, Creative and hopefully, Allergan. PLEASE,
PLEASE, PLEASE do NOT base any of your investment decisions concerning
CNSI on the POSSIBILITY that you think/hope/wish/pray that it will be
bought out. A merger may or may NOT happen and, if it does occur, a
sale/acquisition may NOT take place for months or years from now and
at a price NOT favorable to your entry price or average price;
So, what part of these two paragraphs do you not like--
there are a couple things which raise my eyebrows...and those
are starred--that is royalties dont come until drug is on
the market I should think, and I don't think Cerestat
has any options but the NIH grant/orphan.
Apologies to "YukonHusky" for only posting these two
paragraphs, I know it gives an imcomplete picture, but
hopefully folks will take the link over and read
everything.
I guess a call to the company is finally in order to
touch on a few of the issues as well. Probably cnsi
will not want to sound too optimistic for awhile,
there was some speculation that they might want to
be getting their shares now while the market is
still punishing cnsi.
--Mike |
